Published in Cancer Law Weekly, June 26th, 2004
Presenting the findings at the American Society of Clinical Oncology (ASCO) meeting, Aman Buzdar, MD, professor in the Department of Breast Medical Oncology at M.D. Anderson, reported that more than 65% of early stage, HER-2 positive patients experienced a complete response rate after receiving Herceptin with chemotherapy compared to 26% of patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.